Dr. Christopher V. Crosby, M.D., PH.D.
Mohs Surgery (MOHS-Micrographic Surgery Physician)
8860 Center Dr, Suite 300
La Mesa, CA 91942
Who else practices at this address →
San Diego County includes primary care (1% of residents) and mental health (1% of residents) shortage areas. About shortage areas
- Medicare participating
At a glance
- Medical school
- Medical University of South Carolina College of Medicine (2005)
- Years since graduation
- 21
- In the NPI registry since
- 2008
- Medicare patients seen, 2024
- 829
Licensed in California since 2009, according to the Medical Board of California. We show license dates only for the states that publish them in bulk; see which states do. For other states, check the state medical board.
The NPI date is when this clinician registered for a National Provider Identifier, the billing number used on health claims. It is not a license, graduation or board-certification date. NPIs were first issued in May 2005 and became required on claims in 2007–2008, so an early date usually means the clinician was already in practice before then. What an NPI is
Education and training
- 2005Medical school: Medical University of South Carolina College of Medicine
- 2008Registered with an NPI (national billing number; not a license date) — NPIs began in 2005, so practice likely started earlier
Undergraduate school, residency, fellowship, licensing exams and board certification aren’t in public federal data. Board certification can be confirmed with the certifying board (ABMS member boards for MDs, AOA boards for DOs).
Specialties and state licenses
-
MOHS-Micrographic Surgery Physician primary
CA license A107312 (first issued 2009; current) -
Dermatology Physician
CA license A107312 (first issued 2009; current) · GA license 058457 -
Procedural Dermatology Physician
CA license A107312 (first issued 2009; current)
As reported to the NPI registry. To confirm a license is current, check the state medical board.
Where they work
Medical groups
- Grossmont Dermatology Medical Clinic (10 clinicians)
Hospitals this clinician lists with Medicare, and groups they bill Medicare through (Care Compare). Affiliation doesn’t mean they see patients at every location.
Medicare patients and services
- Medicare patients, 2024
- 829
- Services billed
- 4,547
- Patients’ average age
- 78
| Service | Times | Patients |
|---|---|---|
| Destruction of precancer skin growth, 2-14 growths | 791 | 140 |
| Pathology examination of tissue using a microscope, intermediate complexity | 519 | 294 |
| Established patient office or other outpatient visit, 10-19 minutes | 381 | 304 |
| Removal and microscopic exam of growth of head, neck, hands, feet, or genitals, 1-5 tissue blocks | 376 | 307 |
| Removal and microscopic exam of growth of head, neck, hands, feet, or genitals, each additional stage, 1-5 tissue blocks | 293 | 181 |
| Established patient office or other outpatient visit, 20-29 minutes | 254 | 196 |
| Destruction of precancer skin growth, 1 growth | 234 | 168 |
| Complicated repair of wound of forehead, cheeks, chin, mouth, neck, underarms, genitals, hands, or feet, 2.6-7.5 cm | 147 | 133 |
| Pathology examination of tissue using a microscope, moderately low complexity | 107 | 88 |
| Complicated repair of wound of scalp, arms, or legs, 2.6-7.5 cm | 96 | 90 |
Medicare fee-for-service only. CMS leaves out services billed for fewer than 11 patients. These figures describe a practice’s Medicare work; they aren’t a measure of quality.
Medicare prescriptions
| Drug | Prescriptions |
|---|---|
| Doxycycline Hyclate Other prescribers in La Mesa, CA | 57 |
| Cephalexin Other prescribers in La Mesa, CA | 41 |
| Mupirocin Other prescribers in La Mesa, CA | 40 |
| Ciclopirox (ciclopirox olamine) | 21 |
| Ketoconazole Other prescribers in La Mesa, CA | 18 |
| Triamcinolone Acetonide Other prescribers in La Mesa, CA | 18 |
| Desonide | 14 |
| Ciclopirox Other prescribers in La Mesa, CA | 13 |
| Otezla (apremilast) Other prescribers in La Mesa, CA | 13 |
| Fluticasone Propionate Other prescribers in La Mesa, CA | 12 |
Prescriptions filled under Medicare Part D, including refills. CMS leaves out drugs prescribed fewer than 11 times.
Payments from drug and device companies
In 2025, 8 companies reported 40 payments worth $1,044 in total to this clinician.
| Janssen Biotech, Inc. | $444 |
|---|---|
| AbbVie Inc. | $234 |
| Genzyme Corporation | $177 |
| Leo Pharma Inc. | $56.19 |
| UCB, Inc. | $53.07 |
| Regeneron Healthcare Solutions, Inc. | $39.09 |
| Medline Industries LP | $20.86 |
| Pfizer Inc. | $19.71 |
| Food and Beverage | $949 |
|---|---|
| Education | $94.99 |
What the payments were for
| Company | What it was for | Amount |
|---|---|---|
| Janssen Biotech, Inc. Dec 1, 2025 | Education TREMFYA · Immunology · in-kind | $94.99 |
Each payment as the company reported it, with the products it named. Meals are counted in the totals above but not listed one by one.
From CMS Open Payments. A payment is not evidence of wrongdoing; many are for consulting, teaching or meals. Clinicians can review and dispute their records with CMS.
Industry-funded research
Named as a principal investigator on 5 industry-funded studies in 2025, from 4 companies. The companies reported $137,564 in research payments for these studies, mostly to the institutions running them.
- A Study to Investigate Vaccine Responses in Subcutaneous Amlitelimab Treated Atopic Dermatitis Participants Aged 18 Years and Older Compared With Placebo
Sanofi US Services Inc. · Completed · NCT06015308 - Study to Evaluate Safety, Efficacy and Immunogenicity of Acne mRNA Vaccine in Adults With Moderate to Severe Acne
Sanofi Pasteur Inc. · Recruiting · NCT06316297 - A Phase 3, 52-Week, Multicenter, Randomized, Placebo-controlled, Double-blind Study to Assess the Efficacy, Safety, and Tolerability of Rocatinlimab in Adult Subjects With Prurigo Nodularis Who Are Inadequately Contro…
Amgen Inc. - Study to Evaluate the Efficacy and Safety of Deuruxolitinib in Adolescents With Severe Alopecia Areata
Sun Pharmaceutical Industries Inc. - A Phase 2 Study to Evaluate the Efficacy and Safety of SAR444656 Compared With Placebo in Adult Participants With Moderate to Severe Hidradenitis Suppurativa
Sanofi US Services Inc. · Terminated · NCT06028230
From CMS Open Payments research payments, where companies name up to five principal investigators per payment. Research payments usually go to hospitals, universities and research sites, not to the investigator personally. A payment is not evidence of wrongdoing.